Perrigo Says FDA Approved Its Oral Contraceptive Pill for OTC Use
Provided by
Dow Jones
By Will Feuer
Healthcare product and pharmaceuticals manufacturer Perrigo said the U.S. Food and Drug Administration has approved the company's oral contraceptive Opill for over-the-counter use in all ages.
Opill will be the first-ever birth control pill available over-the-counter without needing a doctor's prescription in the U.S. The oral contraceptive will be sold in stores and online at leading retailers across the U.S. early in the first quarter of 2024, Perrigo said.
Shares rose 5.8% to $35.00 in premarket trading Thursday.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
July 13, 2023 09:10 ET (13:10 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness